The significance of ‘pipefill’ in two generic drug damages awards

In early 2017 the Federal Court issued decisions involving two significant damages awards under s. 8 of the Patented Medicines (Notice of Compliance) Regulations. An important component of these damages awards...

Already a subscriber? Click here to view full article